Stifel Financial’s Galmed Pharmaceuticals GLMD Stock Holding History

Stifel Financial’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-57	Closed	-$61K	–	2916
2019 Q4	$61K	Sell	57 -9	-14%	-$7.73K	﹤0.01%	2914
2019 Q3	$52K	Sell	66 -21	-24%	-$21.1K	﹤0.01%	2799
2019 Q2	$114K	Buy	87 +19	+28%	+$24.5K	﹤0.01%	2814
2019 Q1	$102K	Sell	68 -24	-26%	-$34.9K	﹤0.01%	2695
2018 Q4	$113K	Sell	92 -2	-2%	-$3.49K	﹤0.01%	2547
2018 Q3	$229K	Sell	94 -14	-13%	-$32.8K	﹤0.01%	2504
2018 Q2	$234K	Buy	+108	New	+$156K	﹤0.01%	2452

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

RCG

Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Stifel Financial's GLMD Position: Q1 2020 in Review

Stifel Financial sold out of Galmed Pharmaceuticals (GLMD) in Q1 2020, closing a stake of 57 shares — an estimated $61K sold.

Stifel Financial first reported a position in GLMD in Q2 2018 and held it in 7 quarters. The position peaked at $234K in Q2 2018. 31 funds tracked by Wall St. Rank hold GLMD as of Q1 2020.

Stifel Financial reported no remaining Galmed Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Stifel Financial sold 57 Galmed Pharmaceuticals shares in Q1 2020, an estimated $61K.
Stifel Financial first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Stifel Financial's Galmed Pharmaceuticals position peaked at $234K in Q2 2018.
31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2020.

Based on Stifel Financial's 13F filing for Q1 2020, filed 14 May 2020.